MUC16 has in combination with other serum tumor markers been shown to be associated with survival but has to our knowledge not previously been shown to be an independent factor after adjusting for all other clinically used prognostic factors in previously untreated MBC[5, 6]. This evidence concerns the gene MUC16 and neoplasm.